Lv3
360 积分 2021-08-10 加入
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
2小时前
待确认
Summary of a Public FDA Workshop: Model Informed Drug Development Approaches for Immunogenicity Assessments
1个月前
已完结
Novel 17-Plex Flow Cytometry Assay for Comprehensive Immunophenotyping and Characterization of Plasma Cells (PC) in Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients
1个月前
已完结
Novel 17-Plex Flow Cytometry Assay for Comprehensive Immunophenotyping and Characterization of Plasma Cells (PC) in Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients
1个月前
已关闭
Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry
2个月前
已完结
Immunohistochemistry and Flow Cytometry in Bone Marrow Haematopathology
2个月前
已完结
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma
2个月前
已完结
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
2个月前
已完结
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
3个月前
已完结
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
4个月前
已完结
皖公网安备34019202002308
